April 23 (Reuters) - Inspire Pharmaceuticals Inc ISPH.O said it will discontinue development of its epinastine nasal spray, after a late-stage trial to treat seasonal allergic rhinitis failed to meet the main goal.
The company said its analysis of the overall data in this program and the current competitive environment in allergic rhinitis indicate that epinastine nasal spray does not show potential to meet its desired product profile in the United States.
The 14-day trial, which included 798 patients, evaluated two concentrations of epinastine at two spray volumes, compared to placebo.
Both the epinastine treatment groups did not show statistical significance in treating rhinitis, compared to placebo.
The company said the drug was well-tolerated and there were no safety concerns in the trial.
Inspire acquired exclusive rights in 2006 from Boehringer Ingelheim International to develop and market epinastine nasal spray in the United States and Canada for the treatment of rhinitis. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Anil D‘Silva)